Search the Newsreel

Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $126.85, Implies 22% Upside

Analysts have raised the average 12-month price target for Spyre Therapeutics, Inc. (SYRE) stock to $126.85, up from $124.71, with individual forecasts ranging from $115 to $140. This new target suggests a potential upside of approximately 22% from its August 12 closing price. The …

Price to book forward of Spyre Therapeutics, Inc – SWB:3920

This article provides financial information for Spyre Therapeutics, Inc. (SWB:3920) on the Stuttgart Stock Exchange, specifically focusing on its price-to-book forward ratio. It also highlights the various products, community features, and business solutions offered by TradingView, the platform hosting this financial data.

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says

BTIG Research has increased its price target for Spyre Therapeutics (NASDAQ:SYRE) to $132 from $112, maintaining a "Buy" rating and suggesting a 25.32% upside. This positive outlook follows Spyre Therapeutics beating quarterly earnings expectations, though insiders have sold a significant amount of stock recently. …

SYRE Maintained by BTIG -- Price Target Raised to $132.00

BTIG analyst Julian Harrison has maintained a 'Buy' rating for Spyre Therapeutics (SYRE) and raised its price target to $132.00 from $112.00. While analysts show growing confidence in SYRE's potential, the company has a low GF Score™ of 26/100, indicating weaknesses in profitability and …

Spyre Therapeutics Insider Sold Shares Worth $2,404,190, According to a Recent SEC Filing

An insider at Spyre Therapeutics (SYRE) has reportedly sold shares valued at $2,404,190, according to a recent SEC filing. This transaction follows other insider sales and occurs as the company launches a new program and a mid-stage trial for a drug combination to treat …

Spyre Therapeutics, Inc. $SYRE Shares Bought by Bank of America Corp DE

Bank of America Corp DE significantly increased its stake in Spyre Therapeutics (NASDAQ:SYRE) by 192.6% in the first quarter, now holding 1.23 million shares valued at approximately $61.9 million. Institutional investors collectively own 80.39% of the company, and analysts maintain a "Moderate Buy" rating …

Spyre Therapeutics (NASDAQ:SYRE) Director Sells 18,000 Shares

Spyre Therapeutics (NASDAQ:SYRE) Director Jeffrey Albers sold 18,000 shares of the company's stock for $1,881,900, reducing his holdings by 65.79%. The transaction occurred as Spyre shares traded near record highs and the company reported strong quarterly earnings, beating analyst expectations. Despite the insider sale, …

Spyre Therapeutics (SYRE) director logs 5,000-share option exercise and 23,000-share sale

Jeffrey W. Albers, a director at Spyre Therapeutics (SYRE), exercised stock options for 5,000 shares and sold a total of 23,000 shares on August 7, 2026. The sales, which included indirect ownership through Sessions LLC, were executed at weighted average prices slightly above $104 …

Spyre Therapeutics director Albers sells $2.4m in stock

Jeffrey W. Albers, a director at Spyre Therapeutics (NASDAQ:SYRE), sold 23,000 shares of common stock totaling approximately $2.4 million on August 7, 2026, under a Rule 10b5-1 trading plan. The sales occurred while the stock was near its 52-week high, with InvestingPro analysis indicating …

Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa

Spyre Therapeutics has initiated a Phase 2 trial, SKYLIGHT, for SPY772, a combination therapy targeting hidradenitis suppurativa (HS). The trial will evaluate the dual inhibition of TL1A and IL-17A/F using SPY072 and bimekizumab, with topline data expected in late 2027 or early 2028. This …

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

Spyre Therapeutics has announced the launch of its SPY772 program, a combination therapy involving long-acting anti-TL1A and anti-IL-17A/F antibodies, and the initiation of the Phase 2 SKYLIGHT trial for Hidradenitis Suppurativa (HS). The SKYLIGHT trial will evaluate the dual inhibition of TL1A and IL-17A/F …

Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data?

Spyre Therapeutics has shown exceptional returns over the past three years, with its stock returning roughly 7x, but current valuations suggest it is expensive. The company recently announced positive Phase 2 data for its ulcerative colitis programs, which could support higher growth expectations. However, …

Price to sales forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE

This article displays the "Price to sales forward" metric for Spyre Therapeutics, Inc. (NASDAQ: SYRE) on TradingView. It appears to be a financial data page rather than a detailed analytical article, offering a single data point within the financial overview of the company.

Spyre Therapeutics, Inc. SEC Filing (Aug 7, 2026)

This article reports on Spyre Therapeutics, Inc.'s SEC Form 144 filing from August 7, 2026. The filing details a proposed sale of 18,000 shares of common stock by an individual, acquired through an open market purchase in June 2022, with an aggregate market value …

Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by Wall Street Zen

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment …

Price to earnings forward of Spyre Therapeutics, Inc – DUS:3920

This article provides financial information for Spyre Therapeutics, Inc. trading on the Dusseldorf Stock Exchange under the ticker DUS:3920. It specifically mentions the "Price to earnings forward" metric but does not display any actual values, indicating the market is closed with no trades. The …

Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock

Cameron Turtle, CEO of Spyre Therapeutics (NASDAQ:SYRE), sold 15,000 shares of company stock worth over $1.43 million on August 3, 2026, as part of a pre-arranged trading plan. Despite these insider sales, the stock has seen a significant 554% gain over the past year …

Spyre Therapeutics (SYRE) CFO sells 7,500 shares after option exercise

Spyre Therapeutics (SYRE) CFO Scott L. Burrows exercised stock options for 7,500 shares at $14.50 each and subsequently sold all 7,500 shares in three transactions at weighted average prices between $95.21 and $97.10. These transactions were executed pursuant to a Rule 10b5-1 trading plan …

Spyre Therapeutics (SYRE) CEO trades 15,000 shares under 10b5-1 plan

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on August 3, 2026, across five open-market transactions. These sales were conducted under a Rule 10b5-1 trading plan adopted in June 2025, with weighted average prices ranging from $93.97 to $97.46 per share. …

Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.43, Implies 14% Upside

Analysts have raised the average 12-month price target for Spyre Therapeutics, Inc. (SYRE) stock to $119.43 from $105.79, implying a potential upside of 14% based on the August 4th closing price. The consensus rating from 16 analysts remains a "Buy," with 15 Buys and …

SPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88

Raymond James has increased its target price for SPYRE THERAPEUTICS INC (SYRE.O) to $121 from $88. This information comes from a Reuters report published on August 5, 2026. The article's content reflects only the author's opinion and is not intended as investment advice.

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses

Spyre Therapeutics (SYRE) reported a Q2 2026 loss of 36 cents per share, which was narrower than the estimated 71 cents. The company, which has no marketed products, saw its operating expenses decrease slightly due to gains from the sale of an in-process R&D …

Spyre Therapeutics, Inc. Q2 2026: Net loss $36.2M, EPS $(0.36) — 10-Q Summary

Spyre Therapeutics, Inc. reported a net loss of $36.2 million for Q2 2026, a slight improvement from the $36.7 million loss in Q2 2025, with diluted loss per share at $(0.36). The company had no product revenue, with results primarily influenced by R&D spending, …

Spyre Therapeutics (NASDAQ:SYRE) Posts Quarterly Earnings Results

Spyre Therapeutics (NASDAQ:SYRE) Sets New 52-Week High Following Strong Earnings

Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Spyre Therapeutics reported its second-quarter 2026 financial results, which included cash and cash equivalents of $772.1 million. The company also provided a corporate update, highlighting progress in its clinical programs for IBD and outlining its financial outlook for the coming year.

Spyre expects six Phase 2 trial readouts in 2026; cash totals $1.1B

Spyre Therapeutics reported Q2 2026 financial results, highlighting positive topline induction data for SPY001 and SPY002 in ulcerative colitis. The company completed enrollment for its Phase 2 SKYWAY basket trial and anticipates six proof-of-concept Phase 2 readouts in 2026. Spyre also reported $1.1453 billion …

Spyre Therapeutics stock hits 52-week high at 105.11 USD By Investing.com

Spyre Therapeutics (SYRE) stock has reached a new 52-week high of $105.11, marking a significant 517.49% increase over the past year and achieving a market capitalization of $9.23 billion. This surge is driven by strong investor confidence and positive phase 2 trial results for …

Spyre Therapeutics (SYRE) Earnings Date and Reports 2026 $SYRE

SYRE (NASDAQ: SYRE) insider schedules 30,000-share stock sale notice

SYRE insider Scott Burrows has filed a Form 144 notice to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 3, 2026, related to the exercise of stock options. The aggregate value of this planned sale is $2,949,900.00. The …

Spyre Therapeutics, Inc. $SYRE is Perceptive Advisors LLC's 7th Largest Position

178,389 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by First Trust Advisors LP